I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Pancreatic cancer (PC), especially its main histological type, pancreatic ductal adenocarcinoma (PDAC), has long been well known as one of the most lethal malignant neoplasms worldwide.\[[@ref1]\] In China, its incidence and mortality rate have also been reported to be remarkably raised in recent years.\[[@ref2]\] Up to now, its overall long-term prognosis remains dismal, although curative resection and adjuvant therapy have achieved some favorable effects in highly selected patients.\[[@ref3][@ref4][@ref5]\] Therefore, survival-associated variables in patients with this malignancy caught much attention. The main identified ones were crucial clinicopathologic and surgical factors, including lymph node metastasis, tumor histology grade, peri-neural invasion, and resection margin.\[[@ref6][@ref7][@ref8][@ref9]\] On the other hand, data on prognostic biomarkers in PC, particularly for resectable patients, were also accumulated.\[[@ref10][@ref11]\] However, further candidates need to be supplemented.

In view of the fact that approximately 70% of PDAC patients died from extensive metastatic disease,\[[@ref1]\] invasion-related molecules in this malignancy, such as those previously reported,\[[@ref12][@ref13][@ref14]\] were of particular importance. Plasminogen activator inhibitor-1 (PAI-1), encoded by SERPINE1, is a specific inhibitory member of plasminogen activation (PA) system.\[[@ref15]\] Except for its key role in acute thrombotic events, PAI-1 was also expected to prevent cancer invasion and metastasis through its inhibition of urokinase-type plasminogen activator, which was demonstrated to be involved in malignant dissemination.\[[@ref15]\] Indeed, there were some published articles showing this metastasis inhibitory effect.\[[@ref16][@ref17][@ref18]\] However, more articles suggested its pro-oncogenic roles.\[[@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] In PC/PDAC, different *in vitro* and *in vivo* experiments also got inconsistent, even opposite results.\[[@ref17][@ref19][@ref23]\] However, those for its prognostic significance in PDAC seem to be more consistent. It was shown that PAI-1 mRNA/protein overexpression tended to predict poor patient survival, but not being statistically significant.\[[@ref25][@ref26]\] The smaller sample size and incomplete staining evaluation criteria (without staining intensity) might be the main limits of these investigations.

The aim of this study was to discover the clinicopathologic and prognostic implications of PAI-1 expression in PDAC, through improvements of aforementioned limits.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The study was conducted in accordance with the *Declaration of Helsinki* and was approved by the Ethics Committee of Peking Union Medical College Hospital (No. JS1178). Being a retrospective study and since data analysis was performed anonymously, this study was exempted from the informed consent from patients.

Patients {#sec2-2}
--------

This study enrolled 93 resected patients with PDAC from September 2004 to December 2008. The inclusion criteria included: (1) without chemo-/chemo-radiation therapy before surgery; (2) underwent curative resection; and (3) histologically confirmed. Fifty-eight patients were male and 35 were female. The age ranged from 34 to 85 years (median: 62 years). The main clinical and pathologic variables of patients are summarized in [Table 1](#T1){ref-type="table"}.

###### 

Relationships between PAI-1 expression and clinicopathologic variables of resectable PDAC

  Variables            *n*   PAI-1 expression, *n*   *χ*^2^   *P*       
  -------------------- ----- ----------------------- -------- --------- -------
  Gender                                                                
   Male                58    30                      28       0.001     0.978
   Female              35    17                      18                 
  Age (years)                                                           
   ≥62                 47    24                      23       0.011     0.915
   \<62                46    24                      22                 
  Tumor site                                                            
   Head                57    30                      27       0.061     0.805
   Nonhead             36    18                      18                 
  Tumor size (cm)                                                       
   \>4                 54    27                      27       0.016     0.899
   ≤4                  37    19                      18                 
  Histological grade                                                    
   G1--G2              64    33                      31       \<0.001   0.988
   G3--G4              29    15                      14                 
  T stage                                                               
   T1--T2              71    39                      32       2.479     0.115
   T3                  20    7                       13                 
  N stage                                                               
   N0                  51    21                      30       3.903     0.048
   N1                  35    22                      13                 

Partial data were not available, and statistics were based on available data. *P* values were derived from the Pearson's Chi-square test (two tailed). PAI-1: Plasminogen activator inhibitor 1; PDAC: Pancreatic ductal adenocarcinoma; G1: Well differentiated; G2: Moderately differentiated; G3: Poorly differentiated; G4: Undifferentiated; T: Tumor; N: Lymph node.

Tissue microarray construction {#sec2-3}
------------------------------

The tissue microarray was constructed using formalin-fixed paraffin-embedded blocks. The construction method was same as our previous report.\[[@ref27]\]

Immunohistochemistry {#sec2-4}
--------------------

A mouse monoclonal antibody for human PAI-1 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) and a two-step staining kit (EnVision ™ plus kit, Dako, Denmark) were used for staining. First, 4-μm-thick slides were mounted, deparaffinized, and rehydrated. After antigen retrieval in an autoclave, sections were incubated with 3% hydrogen peroxide (10 min) to block endogenous peroxidase. Then, slides were sequentially incubated with the primary antibody (dilution: 1: 50) overnight at 4°C and horseradish peroxidase-labeled secondary antibody (30 min). Diaminobenzidine was applied as a chromogen. Finally, those were counterstained with hematoxylin. Nonimmune mouse serum at the same dilution was used as the negative control.

Staining evaluation {#sec2-5}
-------------------

Two experienced pathologists who had no clinicopathologic and follow-up information evaluated the sections, according to the H-score,\[[@ref28]\] a widely used immunostaining evaluation criterion.\[[@ref29][@ref30]\] Similar to a previous study,\[[@ref31]\] the H-score with the largest Youden index (YI) within the receiver operating characteristic (ROC) curve for survival status was adopted as the cutoff value.

Follow-up {#sec2-6}
---------

All patients accepted the postsurgical follow-up (range: 2--87 months; median: 11 months). A total of 61 patients (65.6%) died, and the other 32 (34.4%) were alive.

Statistical analysis {#sec2-7}
--------------------

The H-scores of PAI-1 in tumor and nontumor tissues were compared using Mann-Whitney *U*-test. Chi-square test was applied to determine the relationships between PAI-1 expression and clinicopathologic variables. The prognostic significance of PAI-1 was explored by Kaplan-Meier method and log rank test. Univariate and multivariate Cox regression (proportional hazard model) analysis was adopted for prognostic factor identification. Statistical software package Statistical Package for the Social Sciences version 11.5 (SPSS Inc., Chicago, IL, USA) was employed for all the analyses. A statistical significance was defined when *P* \< 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Expression pattern of plasminogen activator inhibitor 1 in resectable pancreatic ductal adenocarcinoma {#sec2-8}
------------------------------------------------------------------------------------------------------

As shown in Figure [1a](#F1){ref-type="fig"} and [1b](#F1){ref-type="fig"}, the positive staining of PAI-1 was mainly located in the cytoplasm of both tumor and nontumor tissues. In all patients and 74 with matched tumor and nontumor samples, the H-scores in tumor tissues were much higher than those in nontumor ones (95 \[47.5, 180\] vs. 80 \[45, 95\], *Z* = −2.439, *P* = 0.015 and 100 \[46.9, 182.5\] vs. 80 \[45, 95\], *Z* = −2.594, *P* = 0.009, respectively) \[Figure [1c](#F1){ref-type="fig"} and [1d](#F1){ref-type="fig"}\].

![PAI-1 expression in resectable PDAC. (a) High expression in tumor tissue (immunohistochemistry, ×200); (b) Low expression in nontumor tissue (immunohistochemistry, ×200); (c) Comparison of PAI-1 H-scores between all tumor and nontumor tissues (Mann-Whitney *U*-test; *Z* = −2.439, *P* = 0.015); (d) Comparison of PAI-1 H-scores between matched tumor and nontumor tissues (Mann-Whitney *U*-test; *Z* = −2.594, *P* = 0.009). PAI-1: Plasminogen activator inhibitor 1; PDAC: Pancreatic ductal adenocarcinoma.](CMJ-131-2947-g001){#F1}

Prognostic value of plasminogen activator inhibitor 1 in resectable pancreatic ductal adenocarcinoma {#sec2-9}
----------------------------------------------------------------------------------------------------

In the first, the H-score value of PAI-1 (cutoff value: 94.375) with the largest YI in the ROC curve for survival status was selected as the cutoff one \[[Figure 2a](#F2){ref-type="fig"}\]. In contrast to patients' low tumoral PAI-1 expression, those with high PAI-1 expression carried significantly poorer tumor-specific survival (TSS) \[log rank value = 19.00, *P* \< 0.0001, [Figure 2b](#F2){ref-type="fig"}\].

![Prognostic value of PAI-1 in resectable PDAC. (a) The cutoff value determination using the ROC curve of tumoral PAI-1 H-scores for tumor-specific survival status; (b) Tumor-specific survival curves of patients with high or low tumoral PAI-1 expression (log rank value = 19.00, *P* \< 0.0001). PAI-1: Plasminogen activator inhibitor 1; PDAC: Pancreatic ductal adenocarcinoma; ROC: Receiver operating characteristic.](CMJ-131-2947-g002){#F2}

Relationships of plasminogen activator inhibitor 1 with clinicopathologic variables of resectable pancreatic ductal adenocarcinoma {#sec2-10}
----------------------------------------------------------------------------------------------------------------------------------

Using Chi-square analysis, high tumoral PAI-1 expression, based on the same cutoff value, was associated with N1 stage \[22/35 for N1 vs. 21/51 for N0, *χ^2^* = 3.903, *P* = 0.048, [Table 1](#T1){ref-type="table"}\]. No significant associations between PAI-1 expression and other clinicopathologic parameters were found \[P \> 0.05, [Table 1](#T1){ref-type="table"}\].

Identification of prognostic indicators in resectable pancreatic ductal adenocarcinoma {#sec2-11}
--------------------------------------------------------------------------------------

It was revealed by univariate Cox regression analysis that histological grade, *N* stage, and PAI-1 expression were predictors of TSS \[*P* \< 0.05, [Table 2](#T2){ref-type="table"}\]. Multivariately, these factors remained to be significant, thus being independent prognostic determinants \[*P* \< 0.05, [Table 2](#T2){ref-type="table"}\].

###### 

Univariate and multivariate analyses for prognostic indicators of resectable PDAC

  Variables            *n*   Univariate   Multivariate                                           
  -------------------- ----- ------------ -------------- --------- -------------- -------------- -------
  Gender                                                                                         
   Male                58    1.182        0.718--1.945   0.510                                   
   Female              35    1                                                                   
  Age (years)                                                                                    
   ≥62                 47    1.341        0.832--2.159   0.228                                   
   \<62                46    1                                                                   
  Tumor site                                                                                     
   Head                57    1                           0.980                                   
   Nonhead             36    0.994        0.611--1.616                                           
  Tumor size (cm)                                                                                
   \>4                 54    0.807        0.496--1.313   0.387                                   
   ≤4                  37    1                                                                   
  Histological grade                                                                             
   G1--G2              64    1                           0.018     1                             0.001
   G3--G4              29    1.824        1.106--3.005   2725      1.495--4.968                  
  T stage                                                                                        
   T1--T2              71    1                           0.941                                   
   T3                  20    0.978        0.541--1.766                                           
  N stage                                                                                        
   N0                  51    1                           0.010     1                             0.004
   N1                  35    1.940        1.169--3.221   2.372     1.327--4.241                  
  PAI-1 expression                                                                               
   High                48    2.874        1.727--4.782   \<0.001   2.559          1.499--4.367   0.001
   Low                 45    1                                     1                             

Partial data were not available, and statistics were based on available data. *P* values were derived from the univariate and multivariate Cox regression analyses. PDAC: Pancreatic ductal adenocarcinoma; *HR*: Hazard ratio; *CI*: Confidence interval; G1: Well differentiated; G2: Moderately differentiated; G3: Poorly differentiated; G4: Undifferentiated; T: Tumor; N: Lymph node; PAI-1: Plasminogen activator inhibitor 1.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

It was long unexpectedly found that PAI-1 promoted many malignant behaviors of several kinds of cancer cells,\[[@ref19][@ref20][@ref21][@ref22][@ref23][@ref24]\] although it is one of the specific inhibitory members of PA system and was thus thought to inhibit cancer invasion/metastasis.\[[@ref16][@ref17][@ref18]\] Therefore, its biological roles in cancer might vary largely. In PC/PDAC, previous articles revealed that high PAI-1 expression at mRNA and protein levels all tended to be associated with poor patient survival,\[[@ref25][@ref26]\] unlike inconsistent data from *in vitro* and *in vivo* experiments.\[[@ref17][@ref19][@ref23]\] The possible reasons of imperfect statistical results might be attributed to smaller sample size (46 cases)\[[@ref26]\] and defective staining evaluation criteria (absence of staining intensity).\[[@ref25]\] In the present study, we included relatively more patients and used the H-score that considered both positive cell ratio and staining intensity\[[@ref28]\] and wished to make it more comprehensive and reliable than aforementioned ones.\[[@ref25][@ref26]\] Our data showed that PAI-1 expression was remarkably higher in tumor than that in nontumor tissues of PDAC, based on the comparison of all samples and 74 matched ones. Moreover, PAI-1 expression positively correlated with N stage, an important factor that reflects tumor cell dissemination and predicts dismal prognosis in PC,\[[@ref6][@ref7]\] similar with evidence from other cancers.\[[@ref32][@ref33]\] Thus, the data preliminarily provide the histological evidence of PAI-1 as a proto-oncogene in PDAC. However, detailed mechanistic explorations remain to be in need.

More importantly, the prognostic value of PAI-1 expression remains to be elucidated in PDAC, on the basis of previous clues.\[[@ref25][@ref26]\] Using H-score and reasonable cutoff value determination method,\[[@ref25][@ref28]\] we showed that high tumoral PAI-1 expression was significantly related to poor TSS \[[Figure 2b](#F2){ref-type="fig"}\]. Furthermore, PAI-1 expression plus the key clinicopathologic parameters of PDAC, histological grade and N stage, were significant prognostic factors, estimated by univariate Cox regression analysis. In view of its positive correlation with N stage, its influence on patient survival might easily be understood. Subsequent multivariate Cox regression analysis identified PAI-1 expression as one of the independent predictors of postsurgical survival of PDAC. These findings, which are largely consistent with those from other tumor types,\[[@ref32][@ref33][@ref34][@ref35][@ref36][@ref37][@ref38][@ref39]\] suggested that PAI-1 might be a strong biomarker for long-term prognosis of PDAC. All our data support its promoting role in PDAC invasion.\[[@ref19][@ref23]\] In the future, combined evaluation of this molecule and other variables might be of interest. On the other hand, relative molecular mechanisms are also worth further investigation.

However, this work has some limitations, such as its retrospective design and single detection method. Therefore, subsequent prospective and more comprehensive validations might be necessary.

In conclusion, our data indicate that PAI-1 expression is upregulated in PDAC and might serve as a poor prognostic marker.
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